# OnCo record ctdna-monitoring-lead-time (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/ctdna-monitoring-lead-time/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "ctdna-monitoring-lead-time" ;
  schema:name "Lead time in ctDNA monitoring studies"@en ;
  schema:alternateName "ctDNA lead time"@en, "molecular lead time"@en ;
  schema:description "Lead time is the measured gap between a first qualifying positive blood sample and a later clinical event. It depends on who is counted and when tests were done, and it is not extra life."@en ;
  schema:url <https://onco.cc/terms/ctdna-monitoring-lead-time/> ;
  schema:dateModified "2026-11-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lead_time_bias> ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2019.1838>, <https://doi.org/10.1016/j.annonc.2022.11.005>, <https://www.fda.gov/media/183874/download> ;
  onco:tag "biomarker", "measurement", "evidence" ;
  onco:related <https://onco.cc/terms/lead-time-bias/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/technologies/continuous-ctdna-monitoring/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/lead-time-bias/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/>, <https://onco.cc/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/> .
